RecruitingPhase 3

An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant

Vertex Pharmaceuticals Incorporated · NCT06832410

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Status re-checked against ClinicalTrials.gov within the last 12 hours.

This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.

Being studied: Biological/Vaccine

Conditions: Type 1 Diabetes; Kidney Transplant

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Key Inclusion Criteria

Clinical history of T1D with greater than or equal to (≥)5 years of insulin dependence
Taking a stable immunosuppression regimen of tacrolimus and mycophenolate mofetil, mycophenolate sodium, or sirolimus for at least 4 weeks
Consistent use of continuous glucose monitor (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study

Key Exclusion Criteria

Prior islet cell transplant, organ transplant (other than kidney transplant), or cell therapy, except prior pancreatic graft that failed within the first 4 weeks
Participants had >1 kidney transplant procedure

Other protocol defined Inclusion/Exclusion criteria may apply.

Perelman Center for Advanced Medicine - Endocrinology
Philadelphia, PA 19104
Montefiore Clinical and Translational Research Center - Endocrinology
Pittsburgh, PA 15213
UW University Hospital - Endocrinology
Madison, WI 53792